ArticleNature cardiovascular research2022
Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation.
Article in Nature cardiovascular research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Partial downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection.Signal transduction and targeted therapy · 2026Article
- One immune cell to bind them all: platelet contribution to neurodegenerative disease.Molecular neurodegeneration · 2024Review
- Blood cell JAKtivation aggravates cerebral venous thrombosis.Blood advances · 2024Article
- Immunothrombosis versus thrombo-inflammation: platelets in cerebrovascular complications.Research and practice in thrombosis and haemostasis · 2024Article
- Platelet-derived lipids promote insulin secretion of pancreatic β cells.EMBO molecular medicine · 2023Article
- Uncoupling of platelet granule release and integrin activation suggests GPIIb/IIIa as a therapeutic target in COVID-19.Blood advances · 2023Article
- Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress.Research and practice in thrombosis and haemostasis · 2023Article
- Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists.Communications biology · 2023Article
- Platelet glycoprotein V spatio-temporally controls fibrin formation.Nature cardiovascular research · 2023Article
- Antibody-mediated depletion of human CLEC-2 in a novel humanized mouse model.Blood advances · 2023Article
- COVID-19 mRNA vaccine-associated cerebral venous thrombosis: Rare adverse event or coincidence?American journal of hematology · 2023Article
- Podoplanin: A potential therapeutic target for thrombotic diseases.Frontiers in neurology · 2023Review
- Loss of zinc transporters ZIP1 and ZIP3 augments platelet reactivity in response to thrombin and accelerates thrombus formationFrontiers in immunology · 2023Article
- The homophilic CD84 receptor is upregulated on platelets in COVID-19 and sepsis.Thrombosis research · 2022Article
- State of the art in cerebral venous sinus thrombosis animal models.Journal of thrombosis and haemostasis : JTH · 2022Review
- Impaired microtubule dynamics contribute to microthrombocytopenia in RhoB-deficient mice.Blood advances · 2022Article
- Targeting of a Conserved Epitope in Mouse and Human GPVI Differently Affects Receptor Function.International journal of molecular sciences · 2022Article
- Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway.European heart journal open · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Cerebral venous (sinus) thrombosis (CVT) is an unusual manifestation of venous thrombosis causing severe neurological impairment and seizures
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.